nodes	percent_of_prediction	percent_of_DWPC	metapath
Methysergide—HTR7—vas deferens—urinary bladder cancer	0.0908	0.407	CbGeAlD
Methysergide—HTR2A—urine—urinary bladder cancer	0.0141	0.0632	CbGeAlD
Methysergide—SIGMAR1—prostate gland—urinary bladder cancer	0.00949	0.0426	CbGeAlD
Methysergide—SIGMAR1—seminal vesicle—urinary bladder cancer	0.00803	0.036	CbGeAlD
Methysergide—SIGMAR1—smooth muscle tissue—urinary bladder cancer	0.00672	0.0301	CbGeAlD
Methysergide—HTR2B—smooth muscle tissue—urinary bladder cancer	0.0067	0.0301	CbGeAlD
Methysergide—SIGMAR1—urethra—urinary bladder cancer	0.00635	0.0285	CbGeAlD
Methysergide—HTR7—epithelium—urinary bladder cancer	0.00596	0.0267	CbGeAlD
Methysergide—HTR1A—renal system—urinary bladder cancer	0.00578	0.0259	CbGeAlD
Methysergide—HTR7—smooth muscle tissue—urinary bladder cancer	0.00574	0.0257	CbGeAlD
Methysergide—HTR1B—female reproductive system—urinary bladder cancer	0.00574	0.0257	CbGeAlD
Methysergide—HTR1D—female reproductive system—urinary bladder cancer	0.00556	0.0249	CbGeAlD
Methysergide—HTR7—renal system—urinary bladder cancer	0.00553	0.0248	CbGeAlD
Methysergide—HTR2C—female reproductive system—urinary bladder cancer	0.0055	0.0247	CbGeAlD
Methysergide—HTR2B—female reproductive system—urinary bladder cancer	0.00517	0.0232	CbGeAlD
Methysergide—SIGMAR1—vagina—urinary bladder cancer	0.00468	0.021	CbGeAlD
Methysergide—HTR2B—vagina—urinary bladder cancer	0.00467	0.021	CbGeAlD
Methysergide—HTR7—female reproductive system—urinary bladder cancer	0.00443	0.0199	CbGeAlD
Methysergide—HTR2A—epithelium—urinary bladder cancer	0.00372	0.0167	CbGeAlD
Methysergide—HTR2A—smooth muscle tissue—urinary bladder cancer	0.00358	0.0161	CbGeAlD
Methysergide—HTR2A—renal system—urinary bladder cancer	0.00345	0.0155	CbGeAlD
Methysergide—SIGMAR1—lymph node—urinary bladder cancer	0.00303	0.0136	CbGeAlD
Methysergide—HTR2B—lymph node—urinary bladder cancer	0.00302	0.0136	CbGeAlD
Methysergide—HTR2A—female reproductive system—urinary bladder cancer	0.00276	0.0124	CbGeAlD
Methysergide—HTR2A—vagina—urinary bladder cancer	0.0025	0.0112	CbGeAlD
Methysergide—Alopecia—Fluorouracil—urinary bladder cancer	0.00236	0.00304	CcSEcCtD
Methysergide—Flushing—Cisplatin—urinary bladder cancer	0.00235	0.00303	CcSEcCtD
Methysergide—Thrombophlebitis—Methotrexate—urinary bladder cancer	0.00232	0.00299	CcSEcCtD
Methysergide—Back pain—Gemcitabine—urinary bladder cancer	0.00229	0.00295	CcSEcCtD
Methysergide—Polyuria—Methotrexate—urinary bladder cancer	0.00229	0.00295	CcSEcCtD
Methysergide—Blood urea increased—Doxorubicin—urinary bladder cancer	0.00226	0.00291	CcSEcCtD
Methysergide—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.00225	0.00289	CcSEcCtD
Methysergide—Tachycardia—Thiotepa—urinary bladder cancer	0.00224	0.00289	CcSEcCtD
Methysergide—Alopecia—Cisplatin—urinary bladder cancer	0.00224	0.00288	CcSEcCtD
Methysergide—Ill-defined disorder—Gemcitabine—urinary bladder cancer	0.0022	0.00283	CcSEcCtD
Methysergide—Thrombophlebitis—Epirubicin—urinary bladder cancer	0.00217	0.0028	CcSEcCtD
Methysergide—Flushing—Etoposide—urinary bladder cancer	0.00216	0.00277	CcSEcCtD
Methysergide—Malaise—Gemcitabine—urinary bladder cancer	0.00214	0.00275	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00209	0.00269	CcSEcCtD
Methysergide—Paraesthesia—Thiotepa—urinary bladder cancer	0.00206	0.00265	CcSEcCtD
Methysergide—Alopecia—Etoposide—urinary bladder cancer	0.00205	0.00264	CcSEcCtD
Methysergide—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.00205	0.00264	CcSEcCtD
Methysergide—Somnolence—Thiotepa—urinary bladder cancer	0.00204	0.00263	CcSEcCtD
Methysergide—Dyspepsia—Thiotepa—urinary bladder cancer	0.00202	0.0026	CcSEcCtD
Methysergide—Convulsion—Fluorouracil—urinary bladder cancer	0.00202	0.0026	CcSEcCtD
Methysergide—Arthralgia—Gemcitabine—urinary bladder cancer	0.00202	0.00259	CcSEcCtD
Methysergide—Myalgia—Gemcitabine—urinary bladder cancer	0.00202	0.00259	CcSEcCtD
Methysergide—Chest pain—Gemcitabine—urinary bladder cancer	0.00202	0.00259	CcSEcCtD
Methysergide—Thrombophlebitis—Doxorubicin—urinary bladder cancer	0.00201	0.00259	CcSEcCtD
Methysergide—Discomfort—Gemcitabine—urinary bladder cancer	0.00199	0.00256	CcSEcCtD
Methysergide—Malaise—Cisplatin—urinary bladder cancer	0.00199	0.00256	CcSEcCtD
Methysergide—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00198	0.00255	CcSEcCtD
Methysergide—Chest pain—Fluorouracil—urinary bladder cancer	0.00198	0.00255	CcSEcCtD
Methysergide—Myalgia—Fluorouracil—urinary bladder cancer	0.00198	0.00255	CcSEcCtD
Methysergide—Fatigue—Thiotepa—urinary bladder cancer	0.00198	0.00255	CcSEcCtD
Methysergide—Constipation—Thiotepa—urinary bladder cancer	0.00196	0.00253	CcSEcCtD
Methysergide—Pain—Thiotepa—urinary bladder cancer	0.00196	0.00253	CcSEcCtD
Methysergide—Discomfort—Fluorouracil—urinary bladder cancer	0.00196	0.00252	CcSEcCtD
Methysergide—Back pain—Etoposide—urinary bladder cancer	0.00196	0.00252	CcSEcCtD
Methysergide—Oedema—Gemcitabine—urinary bladder cancer	0.00193	0.00249	CcSEcCtD
Methysergide—Convulsion—Cisplatin—urinary bladder cancer	0.00191	0.00246	CcSEcCtD
Methysergide—Oedema—Fluorouracil—urinary bladder cancer	0.0019	0.00245	CcSEcCtD
Methysergide—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00189	0.00244	CcSEcCtD
Methysergide—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.00189	0.00243	CcSEcCtD
Methysergide—Ataxia—Methotrexate—urinary bladder cancer	0.00189	0.00243	CcSEcCtD
Methysergide—Pain in extremity—Epirubicin—urinary bladder cancer	0.00188	0.00242	CcSEcCtD
Methysergide—Myalgia—Cisplatin—urinary bladder cancer	0.00188	0.00242	CcSEcCtD
Methysergide—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00188	0.00242	CcSEcCtD
Methysergide—Ill-defined disorder—Etoposide—urinary bladder cancer	0.00188	0.00241	CcSEcCtD
Methysergide—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00186	0.00239	CcSEcCtD
Methysergide—Discomfort—Cisplatin—urinary bladder cancer	0.00186	0.00239	CcSEcCtD
Methysergide—Tachycardia—Fluorouracil—urinary bladder cancer	0.00185	0.00239	CcSEcCtD
Methysergide—Malaise—Etoposide—urinary bladder cancer	0.00182	0.00235	CcSEcCtD
Methysergide—Abdominal pain—Thiotepa—urinary bladder cancer	0.00182	0.00234	CcSEcCtD
Methysergide—Body temperature increased—Thiotepa—urinary bladder cancer	0.00182	0.00234	CcSEcCtD
Methysergide—Oedema—Cisplatin—urinary bladder cancer	0.0018	0.00232	CcSEcCtD
Methysergide—Ataxia—Epirubicin—urinary bladder cancer	0.00177	0.00228	CcSEcCtD
Methysergide—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.00176	0.00227	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00176	0.00227	CcSEcCtD
Methysergide—Tachycardia—Cisplatin—urinary bladder cancer	0.00176	0.00226	CcSEcCtD
Methysergide—Convulsion—Etoposide—urinary bladder cancer	0.00175	0.00225	CcSEcCtD
Methysergide—Insomnia—Gemcitabine—urinary bladder cancer	0.00175	0.00225	CcSEcCtD
Methysergide—Pain in extremity—Doxorubicin—urinary bladder cancer	0.00174	0.00224	CcSEcCtD
Methysergide—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00174	0.00223	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00173	0.00223	CcSEcCtD
Methysergide—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00172	0.00222	CcSEcCtD
Methysergide—Chest pain—Etoposide—urinary bladder cancer	0.00172	0.00222	CcSEcCtD
Methysergide—Eosinophilia—Methotrexate—urinary bladder cancer	0.00172	0.00221	CcSEcCtD
Methysergide—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.00172	0.00221	CcSEcCtD
Methysergide—Insomnia—Fluorouracil—urinary bladder cancer	0.00172	0.00221	CcSEcCtD
Methysergide—Somnolence—Gemcitabine—urinary bladder cancer	0.00172	0.00221	CcSEcCtD
Methysergide—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00171	0.0022	CcSEcCtD
Methysergide—Discomfort—Etoposide—urinary bladder cancer	0.0017	0.00219	CcSEcCtD
Methysergide—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00169	0.00218	CcSEcCtD
Methysergide—Somnolence—Fluorouracil—urinary bladder cancer	0.00169	0.00217	CcSEcCtD
Methysergide—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00167	0.00215	CcSEcCtD
Methysergide—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00167	0.00215	CcSEcCtD
Methysergide—Fatigue—Gemcitabine—urinary bladder cancer	0.00167	0.00214	CcSEcCtD
Methysergide—Constipation—Gemcitabine—urinary bladder cancer	0.00165	0.00213	CcSEcCtD
Methysergide—Pain—Gemcitabine—urinary bladder cancer	0.00165	0.00213	CcSEcCtD
Methysergide—Asthenia—Thiotepa—urinary bladder cancer	0.00165	0.00212	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00164	0.00211	CcSEcCtD
Methysergide—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00164	0.00211	CcSEcCtD
Methysergide—Ataxia—Doxorubicin—urinary bladder cancer	0.00164	0.00211	CcSEcCtD
Methysergide—Dysuria—Methotrexate—urinary bladder cancer	0.00163	0.00209	CcSEcCtD
Methysergide—Neutropenia—Methotrexate—urinary bladder cancer	0.00163	0.00209	CcSEcCtD
Methysergide—Pain—Fluorouracil—urinary bladder cancer	0.00162	0.00209	CcSEcCtD
Methysergide—Paraesthesia—Cisplatin—urinary bladder cancer	0.00162	0.00208	CcSEcCtD
Methysergide—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00162	0.00208	CcSEcCtD
Methysergide—Tachycardia—Etoposide—urinary bladder cancer	0.00161	0.00207	CcSEcCtD
Methysergide—Eosinophilia—Epirubicin—urinary bladder cancer	0.00161	0.00207	CcSEcCtD
Methysergide—Dyspnoea—Cisplatin—urinary bladder cancer	0.00161	0.00207	CcSEcCtD
Methysergide—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00159	0.00205	CcSEcCtD
Methysergide—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.00159	0.00205	CcSEcCtD
Methysergide—Diarrhoea—Thiotepa—urinary bladder cancer	0.00157	0.00202	CcSEcCtD
Methysergide—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00157	0.00201	CcSEcCtD
Methysergide—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00155	0.002	CcSEcCtD
Methysergide—Drowsiness—Methotrexate—urinary bladder cancer	0.00155	0.00199	CcSEcCtD
Methysergide—Pain—Cisplatin—urinary bladder cancer	0.00154	0.00198	CcSEcCtD
Methysergide—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00153	0.00197	CcSEcCtD
Methysergide—Neutropenia—Epirubicin—urinary bladder cancer	0.00152	0.00196	CcSEcCtD
Methysergide—Dysuria—Epirubicin—urinary bladder cancer	0.00152	0.00196	CcSEcCtD
Methysergide—Dizziness—Thiotepa—urinary bladder cancer	0.00152	0.00195	CcSEcCtD
Methysergide—Body temperature increased—Fluorouracil—urinary bladder cancer	0.0015	0.00193	CcSEcCtD
Methysergide—Eosinophilia—Doxorubicin—urinary bladder cancer	0.00149	0.00192	CcSEcCtD
Methysergide—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00148	0.00191	CcSEcCtD
Methysergide—Paraesthesia—Etoposide—urinary bladder cancer	0.00148	0.00191	CcSEcCtD
Methysergide—Weight increased—Epirubicin—urinary bladder cancer	0.00148	0.0019	CcSEcCtD
Methysergide—Weight decreased—Epirubicin—urinary bladder cancer	0.00147	0.00189	CcSEcCtD
Methysergide—Dyspnoea—Etoposide—urinary bladder cancer	0.00147	0.00189	CcSEcCtD
Methysergide—Somnolence—Etoposide—urinary bladder cancer	0.00147	0.00189	CcSEcCtD
Methysergide—Vomiting—Thiotepa—urinary bladder cancer	0.00146	0.00188	CcSEcCtD
Methysergide—Drowsiness—Epirubicin—urinary bladder cancer	0.00145	0.00187	CcSEcCtD
Methysergide—Rash—Thiotepa—urinary bladder cancer	0.00145	0.00186	CcSEcCtD
Methysergide—Dermatitis—Thiotepa—urinary bladder cancer	0.00145	0.00186	CcSEcCtD
Methysergide—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00142	0.00183	CcSEcCtD
Methysergide—Body temperature increased—Cisplatin—urinary bladder cancer	0.00142	0.00183	CcSEcCtD
Methysergide—Fatigue—Etoposide—urinary bladder cancer	0.00142	0.00183	CcSEcCtD
Methysergide—Constipation—Etoposide—urinary bladder cancer	0.00141	0.00182	CcSEcCtD
Methysergide—Pain—Etoposide—urinary bladder cancer	0.00141	0.00182	CcSEcCtD
Methysergide—Dysuria—Doxorubicin—urinary bladder cancer	0.00141	0.00181	CcSEcCtD
Methysergide—Neutropenia—Doxorubicin—urinary bladder cancer	0.00141	0.00181	CcSEcCtD
Methysergide—Asthenia—Gemcitabine—urinary bladder cancer	0.00139	0.00178	CcSEcCtD
Methysergide—Weight increased—Doxorubicin—urinary bladder cancer	0.00137	0.00176	CcSEcCtD
Methysergide—Nausea—Thiotepa—urinary bladder cancer	0.00136	0.00176	CcSEcCtD
Methysergide—Weight decreased—Doxorubicin—urinary bladder cancer	0.00136	0.00175	CcSEcCtD
Methysergide—Feeling abnormal—Etoposide—urinary bladder cancer	0.00136	0.00175	CcSEcCtD
Methysergide—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00135	0.00174	CcSEcCtD
Methysergide—Drowsiness—Doxorubicin—urinary bladder cancer	0.00134	0.00173	CcSEcCtD
Methysergide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00132	0.0017	CcSEcCtD
Methysergide—Abdominal pain—Etoposide—urinary bladder cancer	0.0013	0.00168	CcSEcCtD
Methysergide—Body temperature increased—Etoposide—urinary bladder cancer	0.0013	0.00168	CcSEcCtD
Methysergide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.0013	0.00167	CcSEcCtD
Methysergide—Asthenia—Cisplatin—urinary bladder cancer	0.00129	0.00166	CcSEcCtD
Methysergide—Oedema peripheral—Epirubicin—urinary bladder cancer	0.00128	0.00165	CcSEcCtD
Methysergide—Dizziness—Fluorouracil—urinary bladder cancer	0.00126	0.00162	CcSEcCtD
Methysergide—Diarrhoea—Cisplatin—urinary bladder cancer	0.00123	0.00159	CcSEcCtD
Methysergide—Alopecia—Methotrexate—urinary bladder cancer	0.00123	0.00158	CcSEcCtD
Methysergide—Vomiting—Gemcitabine—urinary bladder cancer	0.00123	0.00158	CcSEcCtD
Methysergide—Rash—Gemcitabine—urinary bladder cancer	0.00122	0.00157	CcSEcCtD
Methysergide—Dermatitis—Gemcitabine—urinary bladder cancer	0.00122	0.00157	CcSEcCtD
Methysergide—Flushing—Epirubicin—urinary bladder cancer	0.00121	0.00155	CcSEcCtD
Methysergide—Vomiting—Fluorouracil—urinary bladder cancer	0.00121	0.00155	CcSEcCtD
Methysergide—Rash—Fluorouracil—urinary bladder cancer	0.0012	0.00154	CcSEcCtD
Methysergide—Dermatitis—Fluorouracil—urinary bladder cancer	0.0012	0.00154	CcSEcCtD
Methysergide—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00119	0.00153	CcSEcCtD
Methysergide—Asthenia—Etoposide—urinary bladder cancer	0.00118	0.00152	CcSEcCtD
Methysergide—Back pain—Methotrexate—urinary bladder cancer	0.00117	0.00151	CcSEcCtD
Methysergide—Alopecia—Epirubicin—urinary bladder cancer	0.00115	0.00148	CcSEcCtD
Methysergide—Nausea—Gemcitabine—urinary bladder cancer	0.00115	0.00148	CcSEcCtD
Methysergide—Vomiting—Cisplatin—urinary bladder cancer	0.00115	0.00147	CcSEcCtD
Methysergide—Rash—Cisplatin—urinary bladder cancer	0.00114	0.00146	CcSEcCtD
Methysergide—Dermatitis—Cisplatin—urinary bladder cancer	0.00113	0.00146	CcSEcCtD
Methysergide—Diarrhoea—Etoposide—urinary bladder cancer	0.00113	0.00145	CcSEcCtD
Methysergide—Nausea—Fluorouracil—urinary bladder cancer	0.00113	0.00145	CcSEcCtD
Methysergide—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00112	0.00145	CcSEcCtD
Methysergide—Flushing—Doxorubicin—urinary bladder cancer	0.00112	0.00144	CcSEcCtD
Methysergide—Back pain—Epirubicin—urinary bladder cancer	0.0011	0.00141	CcSEcCtD
Methysergide—Malaise—Methotrexate—urinary bladder cancer	0.00109	0.00141	CcSEcCtD
Methysergide—Dizziness—Etoposide—urinary bladder cancer	0.00109	0.0014	CcSEcCtD
Methysergide—Nausea—Cisplatin—urinary bladder cancer	0.00107	0.00138	CcSEcCtD
Methysergide—Alopecia—Doxorubicin—urinary bladder cancer	0.00106	0.00137	CcSEcCtD
Methysergide—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.00105	0.00135	CcSEcCtD
Methysergide—Convulsion—Methotrexate—urinary bladder cancer	0.00105	0.00135	CcSEcCtD
Methysergide—Vomiting—Etoposide—urinary bladder cancer	0.00105	0.00135	CcSEcCtD
Methysergide—Rash—Etoposide—urinary bladder cancer	0.00104	0.00134	CcSEcCtD
Methysergide—Dermatitis—Etoposide—urinary bladder cancer	0.00104	0.00134	CcSEcCtD
Methysergide—Arthralgia—Methotrexate—urinary bladder cancer	0.00103	0.00133	CcSEcCtD
Methysergide—Myalgia—Methotrexate—urinary bladder cancer	0.00103	0.00133	CcSEcCtD
Methysergide—Chest pain—Methotrexate—urinary bladder cancer	0.00103	0.00133	CcSEcCtD
Methysergide—Malaise—Epirubicin—urinary bladder cancer	0.00102	0.00132	CcSEcCtD
Methysergide—Discomfort—Methotrexate—urinary bladder cancer	0.00102	0.00131	CcSEcCtD
Methysergide—Back pain—Doxorubicin—urinary bladder cancer	0.00101	0.00131	CcSEcCtD
Methysergide—Convulsion—Epirubicin—urinary bladder cancer	0.000982	0.00126	CcSEcCtD
Methysergide—Nausea—Etoposide—urinary bladder cancer	0.00098	0.00126	CcSEcCtD
Methysergide—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000973	0.00125	CcSEcCtD
Methysergide—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000968	0.00125	CcSEcCtD
Methysergide—Arthralgia—Epirubicin—urinary bladder cancer	0.000965	0.00124	CcSEcCtD
Methysergide—Chest pain—Epirubicin—urinary bladder cancer	0.000965	0.00124	CcSEcCtD
Methysergide—Myalgia—Epirubicin—urinary bladder cancer	0.000965	0.00124	CcSEcCtD
Methysergide—Discomfort—Epirubicin—urinary bladder cancer	0.000953	0.00123	CcSEcCtD
Methysergide—Malaise—Doxorubicin—urinary bladder cancer	0.000946	0.00122	CcSEcCtD
Methysergide—Oedema—Epirubicin—urinary bladder cancer	0.000925	0.00119	CcSEcCtD
Methysergide—Convulsion—Doxorubicin—urinary bladder cancer	0.000909	0.00117	CcSEcCtD
Methysergide—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000906	0.00117	CcSEcCtD
Methysergide—Tachycardia—Epirubicin—urinary bladder cancer	0.000903	0.00116	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.0009	0.00116	CcSEcCtD
Methysergide—Insomnia—Methotrexate—urinary bladder cancer	0.000894	0.00115	CcSEcCtD
Methysergide—Myalgia—Doxorubicin—urinary bladder cancer	0.000893	0.00115	CcSEcCtD
Methysergide—Chest pain—Doxorubicin—urinary bladder cancer	0.000893	0.00115	CcSEcCtD
Methysergide—Arthralgia—Doxorubicin—urinary bladder cancer	0.000893	0.00115	CcSEcCtD
Methysergide—Paraesthesia—Methotrexate—urinary bladder cancer	0.000887	0.00114	CcSEcCtD
Methysergide—Discomfort—Doxorubicin—urinary bladder cancer	0.000882	0.00114	CcSEcCtD
Methysergide—Dyspnoea—Methotrexate—urinary bladder cancer	0.000881	0.00113	CcSEcCtD
Methysergide—Somnolence—Methotrexate—urinary bladder cancer	0.000879	0.00113	CcSEcCtD
Methysergide—Dyspepsia—Methotrexate—urinary bladder cancer	0.00087	0.00112	CcSEcCtD
Methysergide—Oedema—Doxorubicin—urinary bladder cancer	0.000856	0.0011	CcSEcCtD
Methysergide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000853	0.0011	CcSEcCtD
Methysergide—Fatigue—Methotrexate—urinary bladder cancer	0.000852	0.0011	CcSEcCtD
Methysergide—Pain—Methotrexate—urinary bladder cancer	0.000845	0.00109	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000843	0.00108	CcSEcCtD
Methysergide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000838	0.00108	CcSEcCtD
Methysergide—Insomnia—Epirubicin—urinary bladder cancer	0.000837	0.00108	CcSEcCtD
Methysergide—Tachycardia—Doxorubicin—urinary bladder cancer	0.000835	0.00107	CcSEcCtD
Methysergide—Paraesthesia—Epirubicin—urinary bladder cancer	0.000831	0.00107	CcSEcCtD
Methysergide—Dyspnoea—Epirubicin—urinary bladder cancer	0.000825	0.00106	CcSEcCtD
Methysergide—Somnolence—Epirubicin—urinary bladder cancer	0.000822	0.00106	CcSEcCtD
Methysergide—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000814	0.00105	CcSEcCtD
Methysergide—Dyspepsia—Epirubicin—urinary bladder cancer	0.000814	0.00105	CcSEcCtD
Methysergide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000808	0.00104	CcSEcCtD
Methysergide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000799	0.00103	CcSEcCtD
Methysergide—Fatigue—Epirubicin—urinary bladder cancer	0.000797	0.00103	CcSEcCtD
Methysergide—Pain—Epirubicin—urinary bladder cancer	0.000791	0.00102	CcSEcCtD
Methysergide—Constipation—Epirubicin—urinary bladder cancer	0.000791	0.00102	CcSEcCtD
Methysergide—Abdominal pain—Methotrexate—urinary bladder cancer	0.000781	0.00101	CcSEcCtD
Methysergide—Body temperature increased—Methotrexate—urinary bladder cancer	0.000781	0.00101	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.00078	0.001	CcSEcCtD
Methysergide—Insomnia—Doxorubicin—urinary bladder cancer	0.000774	0.000996	CcSEcCtD
Methysergide—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000768	0.000989	CcSEcCtD
Methysergide—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000763	0.000982	CcSEcCtD
Methysergide—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000762	0.000981	CcSEcCtD
Methysergide—Somnolence—Doxorubicin—urinary bladder cancer	0.000761	0.000979	CcSEcCtD
Methysergide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000756	0.000973	CcSEcCtD
Methysergide—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000753	0.000969	CcSEcCtD
Methysergide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000739	0.000951	CcSEcCtD
Methysergide—Fatigue—Doxorubicin—urinary bladder cancer	0.000738	0.00095	CcSEcCtD
Methysergide—Pain—Doxorubicin—urinary bladder cancer	0.000732	0.000942	CcSEcCtD
Methysergide—Constipation—Doxorubicin—urinary bladder cancer	0.000732	0.000942	CcSEcCtD
Methysergide—Abdominal pain—Epirubicin—urinary bladder cancer	0.000731	0.000941	CcSEcCtD
Methysergide—Body temperature increased—Epirubicin—urinary bladder cancer	0.000731	0.000941	CcSEcCtD
Methysergide—Asthenia—Methotrexate—urinary bladder cancer	0.000709	0.000913	CcSEcCtD
Methysergide—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000705	0.000908	CcSEcCtD
Methysergide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.0007	0.000901	CcSEcCtD
Methysergide—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000677	0.000871	CcSEcCtD
Methysergide—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000677	0.000871	CcSEcCtD
Methysergide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000676	0.00087	CcSEcCtD
Methysergide—Asthenia—Epirubicin—urinary bladder cancer	0.000664	0.000854	CcSEcCtD
Methysergide—Dizziness—Methotrexate—urinary bladder cancer	0.000654	0.000841	CcSEcCtD
Methysergide—Diarrhoea—Epirubicin—urinary bladder cancer	0.000633	0.000814	CcSEcCtD
Methysergide—Vomiting—Methotrexate—urinary bladder cancer	0.000628	0.000809	CcSEcCtD
Methysergide—Rash—Methotrexate—urinary bladder cancer	0.000623	0.000802	CcSEcCtD
Methysergide—Dermatitis—Methotrexate—urinary bladder cancer	0.000623	0.000801	CcSEcCtD
Methysergide—Asthenia—Doxorubicin—urinary bladder cancer	0.000614	0.00079	CcSEcCtD
Methysergide—Dizziness—Epirubicin—urinary bladder cancer	0.000612	0.000787	CcSEcCtD
Methysergide—Vomiting—Epirubicin—urinary bladder cancer	0.000588	0.000757	CcSEcCtD
Methysergide—Nausea—Methotrexate—urinary bladder cancer	0.000587	0.000756	CcSEcCtD
Methysergide—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000586	0.000754	CcSEcCtD
Methysergide—Rash—Epirubicin—urinary bladder cancer	0.000583	0.000751	CcSEcCtD
Methysergide—Dermatitis—Epirubicin—urinary bladder cancer	0.000583	0.00075	CcSEcCtD
Methysergide—Dizziness—Doxorubicin—urinary bladder cancer	0.000566	0.000728	CcSEcCtD
Methysergide—Nausea—Epirubicin—urinary bladder cancer	0.000549	0.000707	CcSEcCtD
Methysergide—Vomiting—Doxorubicin—urinary bladder cancer	0.000544	0.0007	CcSEcCtD
Methysergide—Rash—Doxorubicin—urinary bladder cancer	0.00054	0.000694	CcSEcCtD
Methysergide—Dermatitis—Doxorubicin—urinary bladder cancer	0.000539	0.000694	CcSEcCtD
Methysergide—Nausea—Doxorubicin—urinary bladder cancer	0.000508	0.000654	CcSEcCtD
